NCT05822843View on ClinicalTrials.gov

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

August 2, 2023

Primary Completion Date

January 22, 2025

Study Completion Date

January 22, 2025

Conditions

B-cell Lymphoid Malignancies

Interventions

DRUG

ESG206

Administered via intravenous (IV) infusion

Trial Locations (1)

Unknown

Beijing Cancer Hospital, Beijing

All Listed Sponsors

lead

Shanghai Escugen Biotechnology Co., Ltd

INDUSTRY